Diabetic Foot Ulcers

• Between 600,000 and 800,000 Americans with diabetes have non-healing wounds 
• 5% of diabetics develop foot ulcers annually
• Each year, more than 50,000 of them require amputation
• 50% of these patients do not survive five years following amputation
• Apligraf results in faster and higher rates of healing with less recurrence than conventional treatment
• Apligraph approved for ulcers of greater than 3 weeks duration

Venous Leg Ulcers

• Affect 500,000-600,000 Americans annually
• Account for 90% of all leg ulcers
• One in five ulcers persist more than two years
• Recurrence is very common
• After persisting one year, chance of healing is far worse
• Apligraph approved for use in ulcers of greater than 4 weeks duration and doubles healing rate of ulcers present more than a year

Apligraf

• The only FDA approved therapy for venous leg ulcers and diabetic foot ulcer
• Provides state of the art wound healing: contains the necessary structural and biological components known to facilitate all major phases of wound healing
• Proven to heal diabetic foot ulcers and venous leg ulcers more quickly than conventional therapies
• Approximates skin structure and barrier function
• The only living bilayered cell therapy
• Stimulates the wound’s intrinsic healing pathway
• Converts chronic non-healing wounds to acute healing wounds
• Heals more wounds quickly with lower incidence of osteomyelitis and fewer amputations
• Allows patients to return to a full life more quickly
• Thoroughly screened for HIV, Hepatitis and other infectious agents.

Back to the article 'Exciting New Treatment'.